Impact of the administration of liposomal amphotericin B in patients with renal function impairment at initiation of treatment

J Chemother. 2010 Aug;22(4):285-7. doi: 10.1179/joc.2010.22.4.285.

Authors

F Alvarez-Lerma¹, F Mariscal, E Quintana, G Rialp, J Diaz-Reganon, M J Pérez San José, B Alvarez-Sanchez; Liposomal Amphotericin B in the ICU Study Group

Collaborators

Liposomal Amphotericin B in the ICU Study Group:
F Mariscal, M J Perez, F Lopez, N Carrasco, E Quintana, G Rialp, F Alvarez-Lerma, J Nolla, F Martinez, M Nieto, J Diaz-Reganon, B Alvarez-Sanchez, B De la Calle, P Gutierrez, J C Solillo, C Blanco, T Puente, A Escorsell, P Castro, C Aragon, A Lander, C Pinilla, F J Gonzalez, L Maillo, M Moreno, C Cisneros, R M Garcia, A Blanco, M V De la Torre, A Navarro, E Mesalles, J Gomez, J J Caceres, N Santana, J Garcia, S Nicolas-Francis, R Casado, Y Sanduende, J L Anton, J C Ballesteros, P J Medina

Affiliation

¹ Servicio de Medicina Intensiva, Hospital Universitari del Mar, Autonomous University of Barcelona, Barcelona, Spain. Falvarez@imas.imim.es

PMID: 20685637
DOI: 10.1179/joc.2010.22.4.285

No abstract available

Publication types

Multicenter Study
Research Support, Non-U.S. Gov't

MeSH terms

Amphotericin B / adverse effects*
Antifungal Agents / adverse effects*
Creatinine / blood
Female
Humans
Kidney / drug effects*
Kidney Diseases / blood
Male
Middle Aged
Mycoses / drug therapy
Retrospective Studies

Substances

Antifungal Agents
liposomal amphotericin B
Amphotericin B
Creatinine